

# Huibin Zhang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3408420/publications.pdf>

Version: 2024-02-01

9  
papers

149  
citations

1307594

7  
h-index

1474206

9  
g-index

9  
all docs

9  
docs citations

9  
times ranked

237  
citing authors

#	ARTICLE	IF	CITATIONS
1	Design, Synthesis, and Biological Evaluation of IRAK4-Targeting PROTACs. ACS Medicinal Chemistry Letters, 2021, 12, 82-87.	2.8	22
2	Proteolysis-targeting chimeras mediate the degradation of bromodomain and extra-terminal domain proteins. Future Medicinal Chemistry, 2020, 12, 1669-1683.	2.3	6
3	Design and synthesis of Imidazo[1,2-b]pyridazine IRAK4 inhibitors for the treatment of mutant MYD88 L265P diffuse large B-cell lymphoma. European Journal of Medicinal Chemistry, 2020, 190, 112092.	5.5	16
4	Targeting the immunity protein kinases for immuno-oncology. European Journal of Medicinal Chemistry, 2019, 163, 413-427.	5.5	12
5	Design, synthesis and biological evaluation of anthranilamide derivatives as potential factor Xa (fXa) inhibitors. Bioorganic and Medicinal Chemistry, 2018, 26, 5987-5999.	3.0	6
6	Design, synthesis and biological evaluation of novel 2,3-dihydroquinazolin-4(1H)-one derivatives as potential fXa inhibitors. European Journal of Medicinal Chemistry, 2017, 125, 411-422.	5.5	18
7	Synthesis and biological evaluation of GPR40/FFAR1 agonists containing 3,5-dimethylisoxazole. European Journal of Medicinal Chemistry, 2016, 116, 46-58.	5.5	24
8	Identification of anthranilamide derivatives as potential factor Xa inhibitors: Drug design, synthesis and biological evaluation. European Journal of Medicinal Chemistry, 2015, 95, 388-399.	5.5	27
9	Identification of Dipeptidyl Peptidase IV Inhibitors: Virtual Screening, Synthesis and Biological Evaluation. Chemical Biology and Drug Design, 2014, 84, 364-377.	3.2	18